Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 47 publications
Evaluation of Innate Immune System, Body Habitus, and Sex on the Pharmacokinetics and Pharmacodynamics of Anetumab Ravtansine in Patients With Cancer.
Journal: Clinical and translational science
Published: December 30, 2024
Combinatorial screen of targeted agents with the PI3K inhibitors inavolisib, alpelisib, duvelisib, and copanlisib in multi-cell type tumor spheroids.
Journal: SLAS discovery : advancing life sciences R & D
Published: November 30, 2024
Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial).
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: September 23, 2024
Phase II Trial of Afatinib in Patients With EGFR-Mutated Solid Tumors Excluding Lung Cancer: Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol A.
Journal: JCO precision oncology
Published: July 10, 2024
Randomized trial of anetumab ravtansine and pembrolizumab compared to pembrolizumab for mesothelioma.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: June 12, 2024
Phase II Study of Osimertinib in Patients With Epidermal Growth Factor Receptor Mutations: Results From the NCI-MATCH ECOG-ACRIN (EAY131) Trial Subprotocol E.
Journal: JCO precision oncology
Published: April 09, 2024
Combination screen in multi-cell type tumor spheroids reveals interaction between aryl hydrocarbon receptor antagonists and E1 ubiquitin-activating enzyme inhibitor.
Journal: SLAS discovery : advancing life sciences R & D
Published: April 03, 2024
The potential to backfill in phase I trials: the National Cancer Institute's Cancer Therapy Evaluation Program experience.
Journal: JNCI cancer spectrum
Published: November 20, 2023
Assessment of Patient-Derived Xenograft Growth and Antitumor Activity: The NCI PDXNet Consensus Recommendations.
Journal: Molecular cancer therapeutics
Published: July 21, 2023
A Pan-Cancer Patient-Derived Xenograft Histology Image Repository with Genomic and Pathologic Annotations Enables Deep Learning Analysis.
Journal: Cancer research
Published: May 04, 2023
The New NCI Precision Medicine Trials.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: March 27, 2023
Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma.
Journal: Cancer research
Published: March 01, 2023
Last Updated: 09/26/2026